Navigation Links
Tumor cells in blood may signal worse prognosis in head and neck cancer patients
Date:12/21/2010

COLUMBUS, Ohio A new study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival. An increased number of circulating tumor cells (CTCs) also correlates with a worse outcome.

Those are the early findings from an ongoing, prospective study of the prognostic importance of CTCs by a team of researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The study is published in the Dec. issue of the Archives of Otolaryngology, Head and Neck Surgery.

"These findings are extremely exciting, and they suggest that the presence of circulating tumor cells in the blood is correlated with reduced disease-free survival," says co-first author Dr. Kris Jatana, assistant professor of otolaryngology-head and neck surgery at The Ohio State University and Nationwide Children's Hospital. "If these results are supported with continued prospective follow-up, CTCs would be used as a prognostic marker to help further individualize therapy."

Squamous cell carcinomas make up 95 percent of the 36,500 new cases of head and neck cancer expected to occur in the United States in 2010, and the estimated 7,900 deaths from the disease. Currently, no prognostic blood test exists for this malignancy.

With 5 billion red blood cells and 7 million white blood cells in just 20 drops of blood (that is, in one milliliter), counting the much-smaller number of CTCs that might be in a patient blood sample specimen is a challenge.

This team of researchers identified CTCs after first removing normal cells so that abnormal cellscancer cellsremained, a method called negative depletion. They eliminated all the red blood cells by rupturing them, then removed healthy white blood cells by labeling them with magnetic nanoparticles and used a strong magnetic field to pull them out of each sample. Finally, the remaining abnormal cells were stained and manually counted.

"We believe our technique is superior to others because it removes normal cells from the blood, allowing for the detection of CTCs in their native state," Jatana says. "Other reported techniques identify only those cells with a specific surface marker, which has the potential to miss abnormal cells."

This study involves 48 patients who underwent surgical intervention for squamous cell cancer of the head and neck, 35 of which had smoked the equivalent of a pack of cigarettes a day for 15 years, and half of them were moderate to heavy alcohol consumers.

"Although smoking and alcohol consumption are a contributing risk factor for developing head and neck cancers, patients who do not use either also can develop the disease," Jatana says. Patients in the study were followed for an average of 19 months after surgery.

To date, no instances of cancer recurrence or disease-related mortality occurred in patients with no CTCs. The study found a correlation between an increasing number of CTCs and a worse prognosis.

"In the future, along with continued follow-up of these patients, we want to further characterize these cells and determine if this technology can be used for early detection of cancer recurrence," Jatana says. "This could help us individualize treatment and optimize outcomes for head and neck cancer patients."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers discover new way to kill pediatric brain tumors
2. Researchers create drug to keep tumor growth switched off
3. Fluorescent probes light up cancerous tumors
4. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
5. Drug for advanced kidney cancer shrinks tumors prior to surgery
6. Researchers discover second protective role for tumor-suppressor
7. Personalizing cancer: Creating biomarkers from tumor DNA
8. Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery
9. Tumor mechanism identified
10. Mayo oral cancer study shows full tumor genome
11. How estrogen feeds breast tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University ... it produces the same kind of electrical energy that the body uses. , ... moving electrons. This flow of electrons out of the battery is generated by moving ...
(Date:7/24/2017)... ... 24, 2017 , ... Cosmetic Town, an online plastic surgery information community, announces ... on a daily basis. , The new video series will feature board-certified doctors ... their practices. , When asked about the new video series, the senior editor ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... in scholarship awards to be awarded annually to and divided between two full-time ... in bringing awareness to Amazonian plant medicine. To apply for the scholarship, students ...
(Date:7/24/2017)... ... 2017 , ... The Topricin Companies, formerly Topical Biomedics, is ... natural, after-burn skin care product, Topricin After Burn Cream. , Overexposure ... conditions, including cancer. In the short term, overexposure to sun, wind and ...
(Date:7/24/2017)... ... , ... Anyone who uses scales know they have limits; a small kitchen ... same scale to dispense medication. The first example is an issue of capacity, while ... is important to have the right balance for the process. METTLER TOLEDO’s new white ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
Breaking Medicine Technology: